Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $16.1 million.

  • Mirum Pharmaceuticals' Cash from Financing Activities rose 316.67% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 158.09%. This contributed to the annual value of $17.7 million for FY2024, which is 94.74% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Cash from Financing Activities of $16.1 million as of Q3 2025, which was up 85.27% from $8.7 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Cash from Financing Activities registered a high of $207.1 million during Q3 2023, and its lowest value of -$329,000 during Q4 2022.
  • In the last 3 years, Mirum Pharmaceuticals' Cash from Financing Activities had a median value of $7.3 million in 2024 and averaged $35.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 263,548.00% in 2021, then plummeted by 153.50% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $615,000 in 2021, then tumbled by 153.50% to -$329,000 in 2022, then spiked by 640.12% to $1.8 million in 2023, then soared by 200.51% to $5.3 million in 2024, then soared by 316.67% to $16.1 million in 2025.
  • Its last three reported values are $16.1 million in Q3 2025, $8.7 million for Q2 2025, and $6.4 million during Q1 2025.